CRTX Cortexyme Inc.

28.31
-5.99  -17%
Previous Close 34.3
Open 35
Price To Book 5.97
Market Cap 760,193,794
Shares 26,852,483
Volume 319,202
Short Ratio
Av. Daily Volume 65,715
Stock charts supplied by TradingView

NewsSee all news

  1. Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

    -- Presentation to be webcast on Cortexyme's website -- Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to

  2. Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update

    — Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer's disease, continues to advance in Phase 2/3 GAIN clinical trial — Following successful May 2019 initial

  3. Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer's Disease 2019

    - Presentation will detail impact of Cortexyme's lead compound, COR388, on ApoE in Alzheimer's Disease patients - CTAD attendees are also invited to educational session focused on Cortexyme's new investigational

  4. Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial

    - International study is evaluating whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt the progression of Alzheimer's disease - GAIN Trial opened for U.S. enrollment in Q2 2019

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 top-line data due 4Q 2021.
COR388 - GAIN
Alzheimer’s disease

Latest News

  1. Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

    -- Presentation to be webcast on Cortexyme's website -- Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to

  2. Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update

    — Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer's disease, continues to advance in Phase 2/3 GAIN clinical trial — Following successful May 2019 initial

  3. Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer's Disease 2019

    - Presentation will detail impact of Cortexyme's lead compound, COR388, on ApoE in Alzheimer's Disease patients - CTAD attendees are also invited to educational session focused on Cortexyme's new investigational

  4. Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial

    - International study is evaluating whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt the progression of Alzheimer's disease - GAIN Trial opened for U.S. enrollment in Q2 2019